MA57021B1 - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents

Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Info

Publication number
MA57021B1
MA57021B1 MA57021A MA57021A MA57021B1 MA 57021 B1 MA57021 B1 MA 57021B1 MA 57021 A MA57021 A MA 57021A MA 57021 A MA57021 A MA 57021A MA 57021 B1 MA57021 B1 MA 57021B1
Authority
MA
Morocco
Prior art keywords
treatment
antibody
biomarker
level
therapy
Prior art date
Application number
MA57021A
Other languages
English (en)
French (fr)
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA57021B1 publication Critical patent/MA57021B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA57021A 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients MA57021B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Publications (1)

Publication Number Publication Date
MA57021B1 true MA57021B1 (fr) 2024-05-31

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45124A MA45124B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
MA57021A MA57021B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA45124A MA45124B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Country Status (27)

Country Link
US (2) US20190195879A1 (OSRAM)
EP (2) EP3916392B1 (OSRAM)
JP (2) JP7066639B2 (OSRAM)
KR (1) KR102416144B1 (OSRAM)
CN (2) CN115932265A (OSRAM)
AU (1) AU2017272608B2 (OSRAM)
BR (1) BR112018074603A2 (OSRAM)
CY (1) CY1124768T1 (OSRAM)
DK (2) DK3916392T3 (OSRAM)
EA (1) EA201892542A1 (OSRAM)
ES (2) ES2981046T3 (OSRAM)
FI (1) FI3916392T3 (OSRAM)
HR (2) HRP20210938T1 (OSRAM)
HU (2) HUE067450T2 (OSRAM)
IL (1) IL263103B2 (OSRAM)
LT (2) LT3916392T (OSRAM)
MA (2) MA45124B1 (OSRAM)
MD (2) MD3916392T2 (OSRAM)
MX (2) MX388502B (OSRAM)
PL (2) PL3916392T3 (OSRAM)
PT (2) PT3916392T (OSRAM)
RS (2) RS62155B1 (OSRAM)
SG (2) SG11201810159TA (OSRAM)
SI (2) SI3916392T1 (OSRAM)
SM (2) SMT202100291T1 (OSRAM)
WO (1) WO2017207574A1 (OSRAM)
ZA (2) ZA201808647B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017032679A1 (en) 2015-08-21 2017-03-02 Morphosys Ag Combinations and uses thereof
AU2017348624B2 (en) 2016-10-28 2024-09-26 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
JP2022532519A (ja) 2019-05-03 2022-07-15 モルフォシス・アーゲー 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
PH12022551021A1 (en) * 2019-10-31 2023-03-06 Morphosys Ag Sequential anti-cd19 therapy
IL292181A (en) * 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
IL303384A (en) * 2020-12-04 2023-08-01 Morphosys Ag Anti-CD19 combination therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1041221A1 (zh) * 1998-08-11 2002-07-05 Idec药物公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2597924C (en) * 2005-02-15 2018-10-02 Duke University Anti-cd19 antibodies and uses in oncology
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008032217A2 (fr) * 2006-09-13 2008-03-20 Glycode Methode d'investigation de la reponse a un traitement par un anticorps monoclonal
ES2659517T3 (es) 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
CA2817842A1 (en) * 2010-11-15 2012-05-24 Medimmune, Llc Combination therapy for b cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PT2744826T (pt) * 2011-08-16 2022-05-19 Morphosys Ag Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina
KR20140064873A (ko) * 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
CA2858906A1 (en) * 2011-12-12 2013-06-20 Pikamab, Inc Predicting responsiveness to antibody maintenance therapy
CN106029098A (zh) * 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
US20170137516A1 (en) 2014-06-16 2017-05-18 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
JP6805137B2 (ja) * 2014-07-11 2020-12-23 アンセルム（アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 血液学的癌を診断するための方法

Also Published As

Publication number Publication date
KR102416144B1 (ko) 2022-07-04
PL3465214T3 (pl) 2021-12-20
CN109313194A (zh) 2019-02-05
SMT202100291T1 (it) 2021-07-12
MD3916392T2 (ro) 2024-10-31
ES2878156T3 (es) 2021-11-18
MA45124B1 (fr) 2021-05-31
KR20190013980A (ko) 2019-02-11
PT3916392T (pt) 2024-06-04
DK3465214T3 (da) 2021-05-31
EP3916392B1 (en) 2024-05-01
CY1124768T1 (el) 2022-11-25
ZA201808647B (en) 2021-05-26
SG10201911958SA (en) 2020-02-27
PT3465214T (pt) 2021-06-30
HUE067450T2 (hu) 2024-10-28
MX388502B (es) 2025-03-20
WO2017207574A1 (en) 2017-12-07
MD3465214T2 (ro) 2021-09-30
ZA202100296B (en) 2025-05-28
EP3916392A1 (en) 2021-12-01
MA45124A (fr) 2017-12-07
US20190195879A1 (en) 2019-06-27
JP2019519770A (ja) 2019-07-11
LT3916392T (lt) 2024-08-26
IL263103A (en) 2018-12-31
IL263103B2 (en) 2023-10-01
MX2018014702A (es) 2019-10-02
SG11201810159TA (en) 2018-12-28
CA3025823A1 (en) 2017-12-07
CN115932265A (zh) 2023-04-07
JP7066639B2 (ja) 2022-05-13
EA201892542A1 (ru) 2019-06-28
BR112018074603A2 (pt) 2019-03-19
HRP20240670T1 (hr) 2024-09-27
SI3916392T1 (sl) 2024-10-30
LT3465214T (lt) 2021-10-11
AU2017272608B2 (en) 2023-08-10
NZ748468A (en) 2025-05-30
IL263103B1 (en) 2023-06-01
RS62155B1 (sr) 2021-08-31
HUE054860T2 (hu) 2021-10-28
DK3916392T3 (da) 2024-05-21
JP7511806B2 (ja) 2024-07-08
EP3465214A1 (en) 2019-04-10
HRP20210938T1 (hr) 2021-09-03
EP3465214B1 (en) 2021-04-28
AU2017272608A1 (en) 2018-12-06
US20220283166A1 (en) 2022-09-08
SMT202400204T1 (it) 2024-09-16
MX2021014963A (es) 2022-02-24
SI3465214T1 (sl) 2021-12-31
RS65540B1 (sr) 2024-06-28
ES2981046T3 (es) 2024-10-07
FI3916392T3 (fi) 2024-06-03
CN109313194B (zh) 2022-11-04
PL3916392T3 (pl) 2024-09-23
JP2022119764A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
MA57021B1 (fr) Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
Lampson et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Varettoni et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms
Zoller et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study
Mercer et al. Expression and function of TNF and IL-1 receptors on human regulatory T cells
Fan et al. Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation
Pan et al. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy
Shinohara et al. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction
Dengler et al. Cellular changes in blood indicate severe respiratory disease during influenza infections in mice
Akhter et al. CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series
Sippert et al. Association of duffy blood group gene polymorphisms with IL8 gene in chronic periodontitis
Worasilchai et al. Monitoring anti-Pythium insidiosum IgG antibodies and (1→ 3)-β-d-Glucan in vascular pythiosis
Tambur et al. HLA-DQ barrier: Effects on cPRA calculations
Kim et al. Pathogenic genotype of major piroplasm surface protein associated with anemia in Theileria orientalis infection in cattle
US10725029B2 (en) Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample
Mitrovic et al. CD 43 expression is associated with inferior survival in the non‐germinal centre B‐cell subgroup of diffuse large B‐cell lymphoma
Isidro-Hernández et al. Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice
Ilhan et al. Leukemic stem cells shall be searched in the bone marrow before “tyrosine kinase inhibitor‐discontinuation” in chronic myeloid leukemia
Dehmel et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long‐term renal allograft outcome
Sun et al. Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration
Flinterman et al. Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk
Yamauchi et al. Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma
Hartling et al. Gene variation in IL-7 receptor (IL-7R) α affects IL-7R response in CD4+ T cells in HIV-infected individuals
HK1211042A1 (en) Inflammation-enabling polypeptides and uses thereof
Vairaktaris et al. A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer